Michelle Wang
Impact in
-
- RNA Research and Splicing
- Ion channel regulation and function
- DNA and Nucleic Acid Chemistry
- Advanced biosensing and bioanalysis techniques
- RNA and protein synthesis mechanisms
- RNA modifications and cancer
- RNA Interference and Gene Delivery
Papers in
-
- Protein Degradation and Inhibitors 4
- RNA Research and Splicing 3
- Protein purification and stability 2
- Oncology 6
- CAR-T cell therapy research 3
- Co-authors
- Filip Van Petegem (1 shared paper)Karl E. Duderstadt (1 shared paper)Kimberly A. Clark (1 shared paper)Daniel L. Minor (1 shared paper)Preston Williams (1 shared paper)Lin Li (1 shared paper)Wendan Ren (1 shared paper)Weili Miao (1 shared paper)
- Journals
- Blood (4 papers)Molecular Cancer Therapeutics (1 paper)European Journal of Medicinal Chemistry (1 paper)Clinical Cancer Research (1 paper)The FASEB Journal (1 paper)
- Partner nations
- United StatesCanadaChina
In The Last Decade
Michelle Wang
23 papers receiving 420 citations
Peers
Comparison fields: 5 of 80
- Molecular Biology 316
- Pharmacology 26
- Cellular and Molecular Neuroscience 40
- Genetics 18
- Cardiology and Cardiovascular Medicine 38
Countries citing papers authored by Michelle Wang
This map shows the geographic impact of Michelle Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Wang more than expected).
Fields of papers citing papers by Michelle Wang
This network shows the impact of papers produced by Michelle Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Wang. The network helps show where Michelle Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Michelle Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 87 | |
| 2 | 2008 | 66 | |
| 3 | 2015 | 53 | |
| 4 | 2009 | 45 | |
| 5 | 2010 | 43 | |
| 6 | 2019 | 24 | |
| 7 | 2022 | 19 | |
| 8 | 2013 | 18 | |
| 9 | 2024 | 12 | |
| 10 | 2015 | 9 | |
| 11 | 2012 | 8 | |
| 12 | 2020 | 7 | |
| 13 | 2021 | 7 | |
| 14 | Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK). | 2007 | 7 |
| 15 | 2017 | 6 | |
| 16 | 2016 | 4 | |
| 17 | 2010 | 3 | |
| 18 | 2019 | 2 | |
| 19 | Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth. | 2008 | 1 |
| 20 | 2019 | 1 |
About Michelle Wang
Michelle Wang is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Genetics and Cardiology and Cardiovascular Medicine, having authored 28 papers that have together received 426 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (4 papers), Lymphoma Diagnosis and Treatment (4 papers), RNA Research and Splicing (3 papers), CAR-T cell therapy research (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Cardiac electrophysiology and arrhythmias (2 papers), Protein purification and stability (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Molecular Biology (316 citations), Pharmacology (26 citations), Cellular and Molecular Neuroscience (40 citations), Genetics (18 citations) and Cardiology and Cardiovascular Medicine (38 citations). Michelle Wang has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Filip Van Petegem, Karl E. Duderstadt, Kimberly A. Clark, Daniel L. Minor, Preston Williams, Lin Li, Wendan Ren, Weili Miao, Yinsheng Wang and Jikui Song. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, European Journal of Medicinal Chemistry, Clinical Cancer Research and The FASEB Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.